Amgen's stock price surged following the FDA's full approval of IMDELLTRA, positioning the company favorably for long-term growth in oncology and signaling increased market confidence.

Brent touched below $63 per barrel on Friday, heading for a fourth consecutive monthly decline – the longest losing streak in over two years.

Stocks declined on the final trading day of the month, even as expectations for a Fed interest rate cut increased, keeping a global equity index poised for its strongest week since June.